drugset
drugset / Trial / NCT03759041

A Study to Assess Efficacy and Safety of SER-287 in Adults With Active Mild-to-Moderate Ulcerative Colitis

NCT03759041 ↗

Phase 2 Terminated 203 enrolled Seres Therapeutics, Inc.
RandomizedParallel-groupTriple-blindTreatment

Summary

A Randomized, Double-Blind, Placebo-Controlled, Multiple Dose, Multicenter Study to Assess Efficacy and Safety of SER-287 in Adults with Active Mild-to-Moderate Ulcerative Colitis

Timeline

Start
2018-12-19
Primary completion
2021-05-28
Completion
2021-10-13

Drugs

EvaluationDrugModalityDoseRoute
Subject SER-287 Other / unclassified — —
Background Vancomycin Other / unclassified — —

Indications

ulcerative colitis